Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Snakebite treatment 'crisis' will put tens of thousands of lives at risk, charity warns

About 5 million people are bitten by snakes every year

Maria Cheng
Monday 07 September 2015 10:03 EDT
Comments
The Australian eastern brown snake, which has enough venom to kill 20 adults with a single bite
The Australian eastern brown snake, which has enough venom to kill 20 adults with a single bite (AFP/Getty Images)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Doctors Without Borders says the world will run out of one of the most effective treatments for snakebites next year, risking the lives of tens of thousands of people, mostly in developing countries.

In a statement, the medical charity warned that existing stockpiles of the anti-venom Fav-Afrique produced by Sanofi Pasteur will expire in June. The company stopped producing the anti-venom last year and has since switched to making a rabies treatment instead.

"We are now facing a real crisis," Dr. Gabriel Alcoba, the charity's snakebite adviser, said in a statement. The aid group, also known by its French acronym MSF, said there would likely be no alternative to replace the Sanofi Pasteur snakebite treatment for at least two years.

Fav-Afrique anti-venom treatment typically costs 0 to 0 (AFP)
Fav-Afrique anti-venom treatment typically costs 0 to 0 (AFP) (AFP/Getty Images)

A spokesman for Sanofi Pasteur said the pharmaceutical was driven out of the market by competitors selling cheaper products and that they announced in 2010 they would stop making anti-venom.

"It's very strange that (health officials) are only realizing this problem five years later," said Alain Bernal, a Sanofi Pasteur spokesman. He said the company has offered to transfer the anti-venom technology to others but "nothing has materialized yet."

About 5 million people are bitten by snakes every year, including 100,000 deaths and several hundred thousand others who suffer amputations or other disabilities. When it's available, the anti-venom treatment typically costs $250 to $500.

Before a meeting this week in Switzerland, MSF called for international agencies to ensure that snakebite treatment is available where needed. MSF said that the World Health Organization should play "a leading role" in solving the problem and criticized the agency for labeling the issue as a neglected condition.

However, WHO said it does not have an internal snakebite expert and there is no formal program within the organization to address it.

Associated Press

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in